TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Explore the NASDAQ:KYMR financials. Find the Kymera financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key ...

Find the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing.

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.